Disinfection by-products (DBPs) are a major group of water contaminants, and their role in causing adverse health outcomes has been subject to extensive epidemiologic and toxicologic research and review ([@b5-ehp-116-1267]; [@b11-ehp-116-1267]; [@b12-ehp-116-1267]; [@b23-ehp-116-1267]; [@b24-ehp-116-1267]; [@b45-ehp-116-1267]; [@b48-ehp-116-1267]; [@b54-ehp-116-1267]; [@b58-ehp-116-1267]). Determination of safe levels in drinking water has been subject to extensive debate, with a wide range of acceptable levels set across the industrialized world \[[@b32-ehp-116-1267]; [@b42-ehp-116-1267]; [@b50-ehp-116-1267]; [@b57-ehp-116-1267]\].

DBPs are formed by the reaction of chemical disinfectants with natural organic matter (NOM) in water ([@b46-ehp-116-1267]; [@b51-ehp-116-1267]; [@b55-ehp-116-1267]). The structure and quantity of NOM in water sources---and hence the quantity and type of DBPs formed---vary with geographic location and season ([@b16-ehp-116-1267]; [@b49-ehp-116-1267]). DBPs commonly found in drinking water include trihalomethanes (THMs) \[often measured as total trihalomethanes (TTHMs)\], halogenated acetic acids (HAAs), and halogenated acetonitriles (HANs), although TTHMs have most often been the focus of previous toxicologic and epidemiologic research. Research to date has focused on the four regulated THMs: chloroform, bromoform, bromodichloromethane (BDCM), and dibromochloromethane (DBCM) ([@b17-ehp-116-1267]). Toxicologic studies have shown THMs may result in adverse effects in laboratory animals, including hepatotoxicity, nephrotoxicity, mutagenesis, carcinogenicity, and adverse reproductive effects ([@b18-ehp-116-1267]; [@b22-ehp-116-1267]; [@b30-ehp-116-1267]; [@b33-ehp-116-1267]; [@b38-ehp-116-1267]; [@b1-ehp-116-1267]).

Maternal DBP exposure has been linked to an elevated risk for a range of reproductive outcomes, including pregnancy loss, prematurity, and low birth weight ([@b21-ehp-116-1267], [@b20-ehp-116-1267]; [@b31-ehp-116-1267]; [@b34-ehp-116-1267], [@b35-ehp-116-1267]; [@b59-ehp-116-1267]; [@b67-ehp-116-1267]), as well as neural tube defects ([@b21-ehp-116-1267]; [@b19-ehp-116-1267]; [@b28-ehp-116-1267]; [@b36-ehp-116-1267]), cardiac defects ([@b29-ehp-116-1267]), urogenital defects ([@b39-ehp-116-1267]), and oral cleft defects ([@b21-ehp-116-1267]). [Table 1](#t1-ehp-116-1267){ref-type="table"} summarizes the most recent research on DBP exposure and birth defects (BDs). Importantly, these studies show significant effects for several adverse birth outcomes at levels of exposure to THMs that have been observed in Australian metropolitan areas, such as Perth ([@b21-ehp-116-1267]; [@b34-ehp-116-1267]).

Overall, findings relating to adverse effects on reproductive health have been equivocal and are often limited by crude exposure measures or implausible retrospective estimates of exposure to DBPs. Because concentrations of NOM and other chemical precursors in source waters vary in both time and place, DBP levels also fluctuate, complicating exposure assessment in epidemiologic studies. Several authors have indicated a number of concerns with existing studies, particularly regarding their failure to account for all exposure pathways or the temporal and spatial variability in DBPs within regions of water supply ([@b24-ehp-116-1267]; [@b45-ehp-116-1267]; [@b48-ehp-116-1267]; [@b52-ehp-116-1267]). Also, in general, studies have not allowed for residential mobility, use of alternative water sources for drinking and bathing, or exposure to water sources outside the home. Dermal absorption of THMs is particularly poorly estimated despite evidence indicating that showering and other forms of immersion are significant sources of exposure ([@b43-ehp-116-1267]; [@b63-ehp-116-1267]; [@b65-ehp-116-1267]).

Given the ongoing controversy surrounding DBPs and adverse pregnancy outcomes, especially regarding associated BDs, a precautionary approach to DBP exposure during pregnancy is somewhat justified. Most industrialized countries have regulated the permitted levels of TTHM in drinking water, and many of these limits are well below the 250 μg/L level currently accepted in Australia ([@b42-ehp-116-1267]): Canada, 80 μg/L ([@b50-ehp-116-1267]); United States, 80 μg/L ([@b57-ehp-116-1267]); and the United Kingdom, 100 μg/L ([@b32-ehp-116-1267]). By international standards, a number of Australian water supplies continue to contain elevated DBP levels. The water supplied to Perth, Western Australia, is distinctive in several respects ([@b25-ehp-116-1267]). Depending on the suburb, the residential supply may be derived from groundwater from aquifers underlying the city, surface water from catchments along the eastern edge of the city, or a mixture of both. Shallow groundwater resources in Perth contain both high levels of the dissolved fraction of NOM \[dissolved organic carbon (DOC), 10--50 mg/L\] and highly variable concentrations of bromide (0--2.2 mg/L), leading to a high fraction of brominated DBP formation ([@b25-ehp-116-1267]). As a percentage of NOM, the DOC in groundwater can range from 7% to 77% ([@b64-ehp-116-1267]). Historical records from the city's water authority, the Water Corporation of Western Australia, indicate that THM levels range from \> 200 μg/L in some water distribution areas to \< 4 μg/L in others. The geographic variation in these levels provides an opportunity to examine the relationship between DBP exposure and adverse outcomes of pregnancy within a discrete geographic area. In this study we compared the prevalence of BDs in urban populations whose residential water supplies contained markedly different THM levels.

Materials and Methods
=====================

Study design
------------

The study used a record-based prevalence design based on the Western Australia Midwives' Notification System and Birth Defects Registry for the years 2000--2004 inclusive.

Water sampling and analysis
---------------------------

We collected water samples at 47 separate locations within the greater Perth metropolitan area in Western Australia ([Figure 1](#f1-ehp-116-1267){ref-type="fig"}) from publicly accessible taps in highly populated areas, including drinking fountains, outdoor taps close to picnic areas in public parks, and cold-water taps located in public toilets, public parks, and popular restaurants. We chose sampling sites at locations where taps would be frequently used, thereby limiting the storage time of water in delivery pipe networks.

We collected the water samples on six separate occasions from April 2005 to March 2006, inclusive. We flushed taps at each location for 2 min before collection. We collected water samples in 40-mL glass vials, each dosed with the quenching agent sodium thiosulfate, to prevent further THM formation once we took samples. We stored the collected samples on ice in an enclosed insulated carrier. During each collection, we filled vials to maximum level to prevent air bubbles upon sealing, to prevent loss of THMs due to volatilization. We collected samples from all 47 locations within an 8-hr period on each sample day and delivered them to the Chemistry Centre of Western Australia for analysis at the completion of each sampling run.

We performed THM water analyses using the "purge and trap" technique for sample concentration and delivery, followed by gas chromatography with mass spectrometric detection (GC/MS) for the separation and quantification of each of the four analytes ([@b56-ehp-116-1267]). In this system, the sample is purged with an unreactive gas and the analytes trapped at a low temperature on an adsorbent trap. The trap is then heated rapidly and the desorbed compounds refocused at the head of a GC chromatographic column for GC/MS analysis. An internal standard is used to correct for slight differences in temperatures and trapping conditions throughout the run. The method is based on the U.S. EPA 5030C (purge-and-trap for aqueous samples) method ([@b56-ehp-116-1267]) and is accredited by the Australian National Association of Testing Authorities. Routine quality controls are performed with each batch of samples, such as replicate analyses, sample spiking, and blank analyses. We analyzed each sample for TTHM concentration (in micrograms per liter) and for the four individual THMs chloroform, bromoform, DBCM, and BDCM.

Data on births and BDs
----------------------

We obtained number of total births and BDs from post codes corresponding to the water sample collection sites for the years 2000--2004 inclusive from the Western Australia Midwives' Notification System and Birth Defects Registry, respectively ([@b6-ehp-116-1267]). These two data sets form part of the comprehensive Western Australia Linked Database, which systematically links available administrative health data within the state using probabilistic matching of patient names and other identifiers ([@b26-ehp-116-1267]). We obtained deidentified records on birth date, post code of maternal residence at time of birth, maternal age, socioeconomic status code for the maternal residence at time of birth (from linked census data), and the presence of BDs. The Western Australia Birth Defects Registry uses multiple sources of case ascertainment to identify BDs in live births, stillbirths, and pregnancies terminated with fetal abnormality. We did not include minor malformations in our analyses unless they were disfiguring or required treatment. Cases with only minor malformations account for approximately 10% of all BDs registered. We did not include terminations in the present data, but these comprise a relatively small proportion of all cases and have been relatively constant for the past few years.

The Midwives' Notification System is statutory and is completed for all live births and stillbirths of ≥ 20 weeks' gestation or birth weight ≥ 400 g. The Birth Defects Registry in Western Australia has a high level of case ascertainment ([@b8-ehp-116-1267], [@b7-ehp-116-1267]).

A BD is defined by the registry as a structural or functional abnormality that is present at conception or occurs before the end of pregnancy and is diagnosed by 6 years of age. We coded each recorded BD using the British Paediatric Association (BPA) International Classification of Diseases, version 9, system ([@b9-ehp-116-1267]). We investigated associations of DBPs with any BD and also with the following major groups of BDs: nervous system defects (BPA codes 74000--74299), cardiovascular defects (BPA 74500--74799), respiratory system defects (BPA 74800--74899), gastrointestinal defects (BPA 74900--75199), urogenital defects (BPA 75200--75399), musculoskeletal defects (BPA 75400--75699), and congenital anomalies of integument (BPA 75700--75799). Because of low case frequencies, we did not examine the following groups separately: congenital anomalies of eye (BPA 74300--74399); congenital anomalies of ear, face, and neck (BPA 74400--74499); chromosome defects (BPA 75800--75899); and all other defects (BPA 24390--24399, 25520--25529, 27000--27099, 27010, 27100--27199, 27700, 28220, 28240--28249, 28600--28620, 35900--35999, 75992, 77100, 77800).

Data analysis
-------------

We used STATA version 9.0 (StataCorp, College Station, TX, USA) for data analysis. We classified collection sites and post codes of maternal residence in three exposure areas: low (TTHM \< 60 μg/L), medium (TTHM \> 60 to \< 130 μg/L), and high (TTHM ≥ 130 μg/L). We the calculated prevalence proportions for any BD and categories of major BDs for low, medium, and high exposure groups. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for any BD and for categories of BDs using binomial logistic regression models, and calculated estimated risks for the medium and high exposure areas using the low exposure area as the comparison group. We adjusted all estimates for maternal age at an individual level using the deidentified and highly complete case data from registry and midwives' records and data on socioeconomic status \[using Socio-Economic Indexes for Areas (SEIFA) coding ([@b2-ehp-116-1267])\]. SEIFA values are supplied by post code and are calculated based on variables including the proportion of families with high incomes, people with a tertiary education, and employees in skilled occupations; low values indicate areas of disadvantage, and high values indicate areas of advantage.

Results
=======

TTHM levels
-----------

We averaged measurements for each collection site over the six collection dates, and identified all post codes as low, medium, or high exposure as described in "Materials and Methods." Average TTHM concentrations (±1 SD) for low, medium, and high exposure areas were 54 ± 16.6 μg/L, 109.3 ± 28.9 μg/L, and 137 ± 24 μg/L, respectively. [Table 2](#t2-ehp-116-1267){ref-type="table"} summarizes area THM levels, including individual THM concentrations. We also assessed the THM levels within each assigned exposure category using analysis of variance. The mean square errors and *F*-test value (*F* = 204292.41; *p* \< 0.00001) indicated highly significant between-group differences and relatively little within-group variability for the specified category cutoff points. Preliminary analysis of HAAs and HANs during the December testing month showed very low HAA and HAN concentrations by international standards (data not shown), so we did not continue monitoring these compounds.

Prevalence of BDs
-----------------

A total of 1,097 individuals with BDs among 20,870 live births were recorded for the years 2000--2004 inclusive in the study region. In each of the years assessed, BD prevalence showed an increasing trend with higher categories of TTHM exposure, with the exception of 2001 ([Table 3](#t3-ehp-116-1267){ref-type="table"}).

Risk estimates
--------------

Women living in high-TTHM areas at the time of birth of their child showed an increased risk of any BD (adjusted OR = 1.22; 95% CI, 1.01--1.48) compared with women living in low-TTHM areas. For individual BDs, we identified a significantly elevated OR for any cardiovascular BD (adjusted OR = 1.62; 95% CI, 1.04--2.51) for women living in high-TTHM areas compared with women living in low-TTHM areas. [Table 4](#t4-ehp-116-1267){ref-type="table"} summarizes all results. We evaluated maternal age as an independent risk factor for BDs and a potential confounder in this analysis. Using maternal age (in 5-year age strata) as a predictor, we calculated an OR of 1.03 (95% CI, 0.98--1.09) for BD overall. Because average maternal age varied slightly by region, we included it as an individual-level covariate in the final model. For the full model with TTHM exposures included, we undertook restricted analysis on mothers \< 35 years of age to explore possible impacts of advanced maternal age. ORs for the restricted population were comparable with the original analysis (data not shown). We also conducted mixed-effect multilevel analyses, but risk estimates did not substantially differ from those using the original regression models, with persistence of the significant findings for overall BD and cardiovascular BD (data not shown).

Discussion
==========

The results from this record-based prevalence study indicate that women living in high-TTHM areas in Perth at the time of birth of their baby have a 22% greater risk of having a baby with any BD. More specifically, classification in the high-exposure group is associated with an increased risk of 62% for having a baby with a cardiovascular defect. In this analysis, results for musculoskeletal and urogenital defects are suggestive but non-significant, with adjusted ORs of 1.48 (95% CI, 0.99--2.21) and 1.40 (95% CI, 0.98--1.99), respectively.

These findings suggest that there may indeed be an area-related effect in Perth, attributable to the city's heterogeneous water supply and quality. As discussed, the differential exposure patterns most likely relate to the quantity of precursors in the source waters, which display a rough latitudinal gradient. The analyses of BD rates by year also suggest that, except for 2001, the trend toward high defect rates for higher THM levels has been consistent. By international standards, a high proportion of the THMs in the areas tested were in the brominated form. Brominated THMs are thought to possess a greater heath risk compared with chloroform, and this largely relates to differences in their metabolism and toxicokinetics ([@b10-ehp-116-1267]). Reproductive and developmental toxicity has been observed in particular with BDCM ([@b3-ehp-116-1267], [@b4-ehp-116-1267]; [@b15-ehp-116-1267]; [@b27-ehp-116-1267]; [@b41-ehp-116-1267]). We assessed low, medium, and high water consumption in a subpopulation of pregnant women living in Perth in 2004--2005 (data not shown). Based on the ingestion rates for the surveyed population, an exposure model estimated that residence in the highest TTHM exposure group ingesting the highest self-reported intake amount of 4.67 L/day will expose a pregnant women to an equivalent of 3.85 μg TTHM/day. Using this estimation technique, an estimated 3.47 μg TTHM/day (90.1%) are brominated THMs (Chisholm K, Cook A, Weinstein P, unpublished data).

These findings are compatible with a critical review that found evidence for a weak association between the presence of any BD and TTHMs; the risk appeared highest for urinary tract BDs specifically ([@b24-ehp-116-1267]). A review published in 2006 formed similar conclusions ([@b54-ehp-116-1267]). Limited research has been conducted on musculoskeletal defects, with weak associatons reported ([@b24-ehp-116-1267]; [@b54-ehp-116-1267]). The present study showed no significance for nervous system defects, which contrasts with results from [@b19-ehp-116-1267] that neural tube defects were significantly associated with exposure to \> 20 μg/L BDCM (OR = 2.5; 95% CI, 1.2--5.1), the same level of BDCM we found in Perth water supplies ([Table 2](#t2-ehp-116-1267){ref-type="table"}).

Recent literature suggests that lower socioeconomic indices are often predictive of higher BD rates ([@b13-ehp-116-1267]; [@b60-ehp-116-1267]), but in this study our regression models did not suggest an obvious relationship between SEIFA, a composite measure of socioeconomic deprivation available at census district levels (which contain, on average, 225 households), and rates of BDs in the suburbs examined. In this study, we aggregated the SEIFA codes to calculate an average by post code, which was the spatial unit of BD data ([Table 2](#t2-ehp-116-1267){ref-type="table"} summarizes the number of post codes per exposure area). In relation to the exposure, areas with higher socioeconomic (SEIFA) scores commonly fell within the highest THM category; that is, mothers resident in the more affluent suburbs were either just as or more likely to be highly exposed to THMs compared with those in socioeconomically deprived suburbs ([Table 2](#t2-ehp-116-1267){ref-type="table"}). This suggests that socioeconomic factors themselves are not a plausible explanation for the observed findings, and---if anything---the spatial relationship between high socioeconomic status and low quality water in the study area may have tended to attenuate the risk estimate. The particular hospital or clinic used for delivery is also unlikely to be a source of error because the system for collecting BD data is consistent across clinics and routinely audited. In addition, differential maternity/obstetric hospital use by location of residence (and hence exposure) is unlikely given the small number of such hospitals in the catchment areas used for the study. We assessed potential confounding by maternal age, but it was not a significant predictor of BDs in most full exposure models (including those with positive findings for THM exposure). The average age of the mothers varied slightly by TTHM exposure region, but we adjusted for possible confounding effects at the individual level using the deidentified case data.

We acknowledge several limitations in this analysis. Because we used an ecologic exposure measure in this study, the use of residential TTHMs to assign individual exposure raises the possibility of exposure misclassification. For example, women may not have lived in the area at the critical time window relevant to formation of BDs (at conception and first trimester for most BDs). A survey of 78 pregnant women in Perth that we conducted in 2004--2005 (data not included) found that 15.6% of participants reported moving residence during their pregnancy. This finding is similar to recent data reported from a cohort of 584 pregnant women recruited from within Sydney between 2004 and 2006. Of these women, 18% moved residences, although this estimate includes residential movement up to 6 months postpartum ([@b47-ehp-116-1267]). If exposure misclassification has occurred as a result of migration, it is likely to be nondifferential, so risk estimates presented in this study may be overly conservative. Because we have not accounted for individual exposure assessment, we have not taken into account contact with other disinfected water sources (e.g., through swimming and work-related exposures). However, a small survey of 54 pregnant women in metropolitan Perth we conducted in 2004 (data not shown) indicated that 68.5% consumed tap water during their pregnancy, suggesting that bottled water is not a commonly used alternative among this population. Rainwater is not commonly used in Western Australia. A total of 96.3% of the women interviewed used publicly supplied water for showering and bathing, indicating that contact with the town supply remains relevant given that inhalation and dermal absorption are important routes of exposure to THMs ([@b40-ehp-116-1267]; [@b62-ehp-116-1267]; [@b65-ehp-116-1267]; [@b66-ehp-116-1267]).

The measurements used were not taken during the same time period as the health outcome, and limited public availability of complete TTHM levels in Perth precludes the reliable use of historical data. The limited DBP data published for the Perth region is consistent with our exposure estimates, but this historical data set consists of, on average, four samples (or fewer) per year and covers only half of the suburbs that we tested in our study (Water Corporation of Western Australia 2002--2003). Many factors are known to affect DBP formation, including pH, contact time, temperature, concentration and properties of NOM, concentration of both chlorine and residual chlorine, and concentration of bromide, and these may be subject to variation seasonally and from year to year ([@b37-ehp-116-1267]; [@b53-ehp-116-1267]). We observed elevated THM levels during the summer months, and we consistently recorded the highest levels at sites within the high-TTHM regions. Because the increases and decreases in THM levels occurred concurrently across all regions by season, the differences between average levels observed within low, medium, and high regions remained consistent. For confidentiality, birth and BD data were not available by date of birth, so we could not subclassify based on season.

Finally, we extracted BD data for this study in 2007, so for children born after 2001, defects not recognized until later in their lives have yet to be ascertained and included in the registry. However, there is no reason to suppose that this process would be differential by post code, and any incomplete ascertainment for more recent years of birth would be similar for all study locations. Western Australian also has only one centralized Birth Defects Registry, with consistent ascertainment and quality assurance protocols, making substantial variability by region unlikely, particularly within the metropolitan area.

It is reasonable to argue that public health benefits from chlorination in terms of microbiologic safety prevail over the conflicting evidence of potential health risks associated with DBP exposure ([@b54-ehp-116-1267]). However, in Australia and other centers that permit elevated DBP levels, parts of the population are exposed to levels higher than those considered prudent by other industrialized countries. We suggest that national or regional authorities that permit higher TTHM levels may need to reexamine their water quality guidelines to reduce avoidable adverse birth outcomes. If a true elevation in risk is confirmed, a massive and costly engineering "fix" to reduce DBP exposure may not necessarily be warranted. Public health interventions in problem regions of low water quality and availability may be as simple as recommending and/or providing bottled water for pregnant women or ensuring adequate filtration of contaminants before consumption.
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###### 

Review of principal associations and risk measures for DBP exposure and BDs.

  Study design, region, reference                                        Exposure range                                          Defect type                    Risk estimate (95% CI)
  ---------------------------------------------------------------------- ------------------------------------------------------- ------------------------------ ------------------------
  Retrospective cohort, Canada ([@b21-ehp-116-1267])                     High (\> 100 μg/L) versus low (\< 50 μg/L) THM levels   Neural tube defects            2.96 (1.26--6.62)
                                                                                                                                 Major cardiac defects          1.83 (0.97--3.92)
                                                                                                                                 Oral cleft defects             3.17 (1.18--7.26)
  Case--control, USA ([@b36-ehp-116-1267])                               High (\> 40 μg/L) and low (\< 5 μg/L) THMs              Neural tube defects            2.10 (1.10--4.00)
                                                                         High (\> 3 μg/L) and low (\< 0.5 μg/L) HANs             Neural tube defects            1.30 (0.60--2.50)
                                                                         High (\> 35 μg/L) and low (\< 3 μg/L) HAAs              Neural tube defects            1.20 (0.50--2.60)
  Retrospective cohort, Sweden ([@b31-ehp-116-1267])                     Chlorinated versus nonchlorinated water                 Major cardiac defects          1.10 (0.90--1.30)
                                                                                                                                 Oral cleft defects             1.10 (0.80--1.60)
  Retrospective cohort, Canada ([@b19-ehp-116-1267])                     High (\> 20 μg/L) and low (\< 5 μg/L) BDCM              Neural tube defects            2.50 (1.20--5.10)
                                                                                                                                 Major cardiac defects          0.30 (0.20--0.70)
                                                                                                                                 Oral cleft defects             0.60 (0.20--0.90)
  Cross-sectional, Norway ([@b29-ehp-116-1267])                          Chlorination and color versus nonchlorinated            All sentinel anomalies         1.18 (1.02--1.36)
                                                                                                                                 Ventricular septal defects     1.81 (1.05--3.09)
                                                                                                                                 Respiratory defects            1.89 (1.00--3.58)
                                                                                                                                 Urinary tract defects          1.46 (1.00--2.13)
  Case--control, Sweden ([@b14-ehp-116-1267])                            High (\> 10 μg/L ) and low (\< 5 μg/L) THMs             Cardiac defects                1.30 (1.08--1.56)
  Case--control, USA ([@b52-ehp-116-1267])                               50--74 μg/L THMs                                        Study 1: Neural tube defects   0.62 (0.26--1.50)
                                                                                                                                 Study 2: Neural tube defects   1.80 (0.26--1.50)
                                                                                                                                 Oral cleft defects             1.00 (0.32--3.40)
  Registry-based cohort, England and Wales (Niewenhuijsen et al. 2008)   High (4 μg/L) versus low (\< 2 μg/L) bromoform          Major cardiac defects          1.18 (1.00--1.39)

###### 

Demographics and TTHM concentrations for exposure areas.

                                                      Area of TTHM exposure                  
  --------------------------------------------------- ----------------------- -------------- ------------
  No. of post codes included in exposure area         9                       5              11
  Average maternal age range (years)                  25--29                  30--34         30--34
  SEIFA[a](#tfn1-ehp-116-1267){ref-type="table-fn"}                                          
   Range                                              945--1,026              1,002--1,100   873--1,082
   Average                                            994.2                   1033.6         982.1
   Median                                             989.8                   1028.0         997.6
  Average THM concentration (μg/L)                                                           
   TTHM                                               54.0                    109.3          137.0
   Chloroform                                         2.0                     9.0            15.0
   Bromoform                                          31.0                    39.5           39.0
   BDCM                                               5.0                     19.5           29.0
   DBCM                                               17.0                    44.0           54.5
  Median THM concentration (μg/L)                                                            
   TTHM                                               51.0                    115.0          140.0
   Chloroform                                         1.0                     8.2            11.0
   Bromoform                                          29.0                    38.0           40.0
   BDCM                                               3.3                     19.0           27.0
   DBCM                                               16.0                    44.5           53.0
  Maximum individual site THM concentration (μg/L)                                           
   TTHM                                               140.0                   160.0          190.0
   Chloroform                                         5.2                     19.0           52.0
   Bromoform                                          54.0                    66.0           78.0
   BDCM                                               13.0                    44.0           57.0
   DBCM                                               28.0                    72.0           81.0
  Minimum individual site THM concentration (μg/L)                                           
   TTHM                                               36.0                    39.0           61.0
   Chloroform                                         1.0                     1.0            2.8
   Bromoform                                          20.0                    6.3            9.6
   BDCM                                               2.6                     3.1            6.8
   DBCM                                               10.0                    12.0           18.0
  25th percentile THM concentration (μg/L)                                                   
   TTHM                                               42.0                    93.25          120.0
   Chloroform                                         1.0                     6.20           8.1
   Bromoform                                          24.0                    33.50          20.0
   BDCM                                               3.2                     14.75          19.0
   DBCM                                               13.0                    34.75          46.0
  75th percentile THM concentration (μg/L)                                                   
   TTHM                                               62.0                    130.0          150.0
   Chloroform                                         3.15                    10.25          16.0
   Bromoform                                          34.0                    47.25          53.0
   BDCM                                               3.8                     24.00          35.0
   DBCM                                               18.0                    53.25          62.0

Low values indicate areas of disadvantage, and high values indicate areas of advantage.

###### 

Number of births, BDs, and BD prevalence for TTHM exposure areas for births within the Perth metropolitan area, 2000--2004 inclusive.

                                             Year                                    
  ------------------------------- ---------- ------- ------- ------- ------- ------- --------
  Low (\< 60 μg/L)                TB (*n*)   518     556     572     639     659     2,944
                                  BD (*n*)   31      31      19      24      29      134
                                  BDP (%)    6.4     5.6     3.3     3.8     4.4     4.6
  Medium (\> 60 to \< 130 μg/L)   TB (*n*)   958     934     930     945     981     4,748
                                  BD (*n*)   58      60      35      42      40      235
                                  BDP (%)    6.4     6.4     3.8     4.4     4.1     5.0
  High (≥ 130 μg/L)               TB (*n*)   2,638   2,666   2,593   2,557   2,724   13,178
                                  BD (*n*)   174     149     146     127     132     728
                                  BDP (%)    7.1     5.6     5.6     5.0     4.8     5.5

Abbreviations: BDP, BD prevalence for exposure area; TB, total number of births for exposure area.

###### 

ORs (95% CIs) for the association between TTHM exposure and any BD or individual BD, 2000--2004 inclusive.

  Birth outcome[a](#tfn3-ehp-116-1267){ref-type="table-fn"}   Case number[b](#tfn4-ehp-116-1267){ref-type="table-fn"}   Adjusted OR (95% CI)[c](#tfn5-ehp-116-1267){ref-type="table-fn"}
  ----------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------
  Any BD                                                                                                                
   Low                                                        134                                                       1.00
   Medium                                                     235                                                       0.98 (0.75--1.28)
   High                                                       728                                                       1.22 (1.01--1.48)[\*](#tfn6-ehp-116-1267){ref-type="table-fn"}
  Cardiovascular (BPA 74500--74799)                                                                                     
   Low                                                        24                                                        1.00
   Medium                                                     55                                                        1.00 (0.55--1.81)
   High                                                       181                                                       1.62 (1.04--2.51)[\*](#tfn6-ehp-116-1267){ref-type="table-fn"}
  Musculoskeletal (BPA 75400--75699)                                                                                    
   Low                                                        29                                                        1.00
   Medium                                                     53                                                        1.05 (0.60--1.83)
   High                                                       200                                                       1.48 (0.99--1.21)
  Gastrointestinal (BPA 74900--75199)                                                                                   
   Low                                                        11                                                        1.00
   Medium                                                     24                                                        1.27 (0.55--2.96)
   High                                                       66                                                        1.20 (0.63--2.30)
  Urogenital (BPA 75200--75399)                                                                                         
   Low                                                        40                                                        1.00
   Medium                                                     76                                                        1.09 (0.68--1.77)
   High                                                       235                                                       1.40 (0.98--1.99)
  Nervous system (BPA 74000--74299)                                                                                     
   Low                                                        6                                                         1.00
   Medium                                                     15                                                        1.78 (0.55--5.80)
   High                                                       38                                                        1.08 (0.41--2.85)
  Respiratory system (BPA 74800--74899)                                                                                 
   Low                                                        2                                                         1.00
   Medium                                                     3                                                         1.06 (0.13--8.87)
   High                                                       12                                                        0.88 (0.18--4.18)
  Integument congenital anomalies (BPA 75700--75799)                                                                    
   Low                                                        13                                                        1.00
   Medium                                                     15                                                        0.91 (0.36--2.33)
   High                                                       8                                                         0.95 (0.49--1.83)

Low, \< 60 μg/L; medium, \> 60 to \< 130 μg/L; high, ≥ 130 μg/L.

Total births for each exposure area: low, 2,944; medium, 4,748; high, 13,178.

Adjusted for maternal age and socioeconomic status.

*p* \< 0.05.
